RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has notified shareholders of amendments to its Proxy Statement related to the issuance of restricted share units to certain executives and directors, after implementing a significant change in its American Depositary Shares ratio. The ADS ratio adjustment, effective August 20, 2024, alters the previous 1:400 ratio to 1:10,000, akin to a one-for-25 reverse ADS split, affecting the number of ADSs referenced in the RSU proposals. This clarification ensures accurate reflection of share distribution post-ratio change in the upcoming Annual General Meeting.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
